We recommend that peripheral blood flow cytometery and measurement of peripheral blood cytokines (e.g. IL-1β, IL-6 and TNF-α) should be performed whenever feasible to further refine the therapeutic decision-making for CRS (34). The gene discussed is TNF; the disease is congenital rubella syndrome.